Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Journey Medical Corp (DERM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/31/2025: DERM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.5
1 Year Target Price $13.5
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 57.93% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 209.22M USD | Price to earnings Ratio - | 1Y Target Price 13.5 |
Price to earnings Ratio - | 1Y Target Price 13.5 | ||
Volume (30-day avg) 4 | Beta 0.81 | 52 Weeks Range 3.54 - 9.40 | Updated Date 01/1/2026 |
52 Weeks Range 3.54 - 9.40 | Updated Date 01/1/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.35 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -14.58% | Operating Margin (TTM) -8.67% |
Management Effectiveness
Return on Assets (TTM) -4.6% | Return on Equity (TTM) -47.05% |
Valuation
Trailing PE - | Forward PE 32.15 | Enterprise Value 209570827 | Price to Sales(TTM) 3.52 |
Enterprise Value 209570827 | Price to Sales(TTM) 3.52 | ||
Enterprise Value to Revenue 3.53 | Enterprise Value to EBITDA 17.72 | Shares Outstanding 21135905 | Shares Floating 14649318 |
Shares Outstanding 21135905 | Shares Floating 14649318 | ||
Percent Insiders 31.39 | Percent Institutions 41.33 |
Upturn AI SWOT
Journey Medical Corp
Company Overview
History and Background
Journey Medical Corp. was founded in 2011 with a mission to acquire and commercialize innovative pharmaceutical products. The company has focused on identifying and licensing late-stage pharmaceutical assets, particularly in dermatology, and bringing them to market through strategic partnerships and targeted marketing efforts. A significant milestone was the acquisition and successful launch of Exciplex. The company has evolved by expanding its product portfolio and strengthening its commercialization capabilities.
Core Business Areas
- Dermatology Products: Journey Medical Corp. primarily focuses on the commercialization of prescription dermatological products. This includes developing and marketing treatments for various skin conditions.
- Acquisition and Licensing: The company actively seeks to acquire or license late-stage pharmaceutical assets, particularly in its core therapeutic areas, to build its product pipeline.
Leadership and Structure
Journey Medical Corp. is led by a management team with experience in the pharmaceutical industry. Specific details on the leadership team and organizational structure are typically found in company filings (e.g., SEC filings) and investor relations sections of their website.
Top Products and Market Share
Key Offerings
- Product Name 1: Exciplex (brimonidine topical solution, 0.33%) - A topical treatment for persistent facial erythema associated with rosacea. Competitors include Galderma's Mirvaso, Syneos Health's Zyclara, and various other topical and oral medications for rosacea. Market share data for specific products like Exciplex is often proprietary or reported in aggregate by market research firms.
Market Dynamics
Industry Overview
The dermatology pharmaceutical market is characterized by significant innovation, with a growing demand for effective treatments for various skin conditions. The market is competitive, with established pharmaceutical giants and smaller specialty companies vying for market share. Factors such as aging populations, increasing awareness of dermatological issues, and advancements in drug delivery systems drive market growth.
Positioning
Journey Medical Corp. positions itself as a specialty pharmaceutical company focused on acquiring and commercializing differentiated dermatological products. Its strategy involves identifying unmet needs and bringing novel therapies to market through a focused commercial approach. Its competitive advantage lies in its ability to identify and acquire promising assets and its expertise in the dermatology market.
Total Addressable Market (TAM)
The total addressable market for dermatology pharmaceuticals is substantial, with estimates varying widely depending on the specific conditions and geographies included. It is valued in the tens of billions of dollars globally. Journey Medical Corp. is positioned to capture a niche within this TAM through its specialized product portfolio.
Upturn SWOT Analysis
Strengths
- Specialized focus on the dermatology market.
- Pipeline of acquired or licensed late-stage assets.
- Experienced management team in pharmaceutical commercialization.
Weaknesses
- Reliance on a limited number of key products.
- Potential challenges in scaling commercial operations.
- Limited brand recognition compared to larger pharmaceutical companies.
Opportunities
- Acquisition of additional promising drug candidates.
- Expansion into new therapeutic areas within dermatology.
- Partnerships for broader market reach and distribution.
Threats
- Intense competition from established players.
- Regulatory hurdles and potential delays in drug approvals.
- Pricing pressures and reimbursement challenges.
- Patent expirations of key products.
Competitors and Market Share
Key Competitors
- Allergan (AbbVie)
- Galderma
- Bausch Health Companies Inc.
- Eisai Co., Ltd.
Competitive Landscape
Journey Medical Corp. operates in a competitive dermatology market dominated by larger, well-established pharmaceutical companies. Its competitive advantages include a focused strategy on niche dermatological products and agile commercialization. However, it faces challenges from the extensive R&D budgets, broad product portfolios, and established market presence of its larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth would be assessed by analyzing revenue trends, product launches, and strategic acquisitions over the past few years. The success of products like Exciplex would be a key indicator of historical growth.
Future Projections: Future projections are typically based on analyst estimates, which consider the company's pipeline, market trends, and competitive landscape. Specific analyst projections are not publicly available without access to financial data terminals.
Recent Initiatives: Recent initiatives may include the acquisition of new product candidates, expansion of sales and marketing efforts, or strategic partnerships to enhance commercial reach.
Summary
Journey Medical Corp. is a specialty pharmaceutical company focused on dermatology, with a key product like Exciplex. Its strength lies in its focused strategy and ability to commercialize niche products. However, it faces significant competition and reliance on a limited product portfolio. Future success will depend on its ability to acquire and successfully launch new assets while navigating market challenges.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K, 10-Q)
- Reputable Financial News Outlets
- Market Research Reports (general industry data)
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Market share data and specific financial figures are estimates and subject to change. Investors should conduct their own due diligence before making any investment decisions. Specific product competitors and market share percentages are illustrative and may not represent precise, up-to-the-minute figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Journey Medical Corp
Exchange NASDAQ | Headquaters Scottsdale, AZ, United States | ||
IPO Launch date 2021-11-12 | Founder, President, CEO & Director Mr. Claude Maraoui | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 41 | Website https://journeymedicalcorp.com |
Full time employees 41 | Website https://journeymedicalcorp.com | ||
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.